Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection. Since the killer T cells targeted a highly conserved protein that does not change from year to year, the adjuvant strategy suggests potential for a universal flu vaccine.
"Most vaccines protect against disease by boosting antibody protection," said lead author post-doctoral fellow Megan MacLeod, PhD. "We have shown that the two adjuvants work in concert to generate memory CD8 T cells, which can kill infected cells. We believe that this strategy of stimulating both the cellular and humoral immune responses holds promise for better vaccines."
Vaccines prepare the immune system to respond quickly to an infection with antibodies, Y-shaped molecules that neutralize or otherwise inactivate pathogens.
Aluminum salts, or alum, have been used for nearly a century as an adjuvant to boost the effectiveness of many vaccines. Surprisingly no one is sure even today exactly how it works. The only other adjuvant approved for use in the United States, monophosphoryl lipid A (MPL), is used by GlaxoSmithKline to boost the antibody response of some of its vaccines.
Dr. MacLeod, senior author Philippa Marrack, PhD, and their colleagues evaluated the responses of mice immunized with influenza vaccines containing no adjuvant, each adjuvant alone and both together. They engineered the vaccine so that any immune defense would be provided by killer T cells, not antibodies. Several weeks after the immunization, they infected the mice with influenza A virus.
They found that unvaccinated mice lost about 15 percent of their body weight in the first eight days after infection, then regained some of that weight by 20 days a
'/>"/>
| Contact: William Allstetter allstetterw@njhealth.org 303-398-1002 National Jewish Health Source:Eurekalert |
Related biology news :
1. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
2. Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients
3. Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says
4. UT Southwestern researchers use drug-radiation combo to eradicate lung cancer
5. Graphene and spintronics combo looks promising
6. Long-term study shows effect of climate change on animal diversity
7. New approach to treating cystic fibrosis lung infection shows promise
8. Research shows Brazilian acai berry antioxidants absorbed by human body
9. Wildfires cause ozone pollution to violate health standards, new study shows
10. New CU-Boulder study shows diversity decreases chances of parasitic disease
11. U of MN study shows link between gene variations and cancer survival
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |